Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Bacterial Gastroenteritis01:18

Bacterial Gastroenteritis

Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid receptor...
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of sickle cell trait with adverse pregnancy outcomes in a population-based cohort.

Acta obstetricia et gynecologica Scandinavica·2023
Same author

Microbiota from Preterm Infants Who Develop Necrotizing Enterocolitis Drives the Neurodevelopment Impairment in a Humanized Mouse Model.

Microorganisms·2023
Same author

Correction to: A randomized controlled trial of oropharyngeal therapy with mother's own milk for premature infants.

Journal of perinatology : official journal of the California Perinatal Association·2023
Same author

A randomized controlled trial of oropharyngeal therapy with mother's own milk for premature infants.

Journal of perinatology : official journal of the California Perinatal Association·2023
Same author

Sickle Cell Trait and Risk for Common Diseases: Evidence from the UK Biobank.

The American journal of medicine·2022
Same author

Association of Sickle Cell Trait with Risk and Mortality of COVID-19: Results from the United Kingdom Biobank.

The American journal of tropical medicine and hygiene·2021
Same journal

The EXTra-uterine Environment for Neonatal Development (EXTEND) - future treatment for prematurity and potentially other congenital disease.

Seminars in pediatric surgery·2026
Same journal

Appendicitis as a model for pediatric surgical quality improvement and standardization.

Seminars in pediatric surgery·2026
Same journal

From FOB to PICU: military trauma systems that changed pediatrics.

Seminars in pediatric surgery·2026
Same journal

Long-term follow-up after surgery for congenital anomalies: A time to complication analysis.

Seminars in pediatric surgery·2026
Same journal

Radio-surgical decision-making in hepatoblastoma in the post-PHITT era: SIOPEL consensus recommendations.

Seminars in pediatric surgery·2026
Same journal

Seminars in pediatric sugery pediatric metabolic and bariatric surgery.

Seminars in pediatric surgery·2026
See all related articles

Related Experiment Video

Updated: May 12, 2026

In Vitro Apical-Out Enteroid Model of Necrotizing Enterocolitis
09:11

In Vitro Apical-Out Enteroid Model of Necrotizing Enterocolitis

Published on: June 8, 2022

Necrotizing enterocolitis: pathophysiology, platelet-activating factor, and probiotics.

Brandy L Frost1, Michael S Caplan

  • 1Department of Pediatrics, NorthShore University HealthSystem, Pritzker School of Medicine, University of Chicago, 2650 Ridge Ave, Walgreen Building, Suite 1505, Evanston, Illinois, USA. bfrost@northshore.org

Seminars in Pediatric Surgery
|April 25, 2013
PubMed
Summary
This summary is machine-generated.

Necrotizing enterocolitis (NEC) remains a serious threat to preterm infants. While probiotics show promise for prevention, optimal use and safety require further investigation for this complex neonatal disease.

More Related Videos

Microfluidic Model of Necrotizing Enterocolitis Incorporating Human Neonatal Intestinal Enteroids and a Dysbiotic Microbiome
06:51

Microfluidic Model of Necrotizing Enterocolitis Incorporating Human Neonatal Intestinal Enteroids and a Dysbiotic Microbiome

Published on: July 28, 2023

Related Experiment Videos

Last Updated: May 12, 2026

In Vitro Apical-Out Enteroid Model of Necrotizing Enterocolitis
09:11

In Vitro Apical-Out Enteroid Model of Necrotizing Enterocolitis

Published on: June 8, 2022

Microfluidic Model of Necrotizing Enterocolitis Incorporating Human Neonatal Intestinal Enteroids and a Dysbiotic Microbiome
06:51

Microfluidic Model of Necrotizing Enterocolitis Incorporating Human Neonatal Intestinal Enteroids and a Dysbiotic Microbiome

Published on: July 28, 2023

Area of Science:

  • Neonatal Medicine
  • Gastroenterology
  • Microbiology

Background:

  • Necrotizing enterocolitis (NEC) is a significant cause of morbidity and mortality in preterm neonates despite medical advances.
  • Platelet-activating factor (PAF) is implicated in NEC pathophysiology, but effective preventative and treatment strategies are limited.
  • Enteral probiotics are a potential preventative measure for NEC, but optimal usage and safety are not fully established.

Purpose of the Study:

  • To review the pathophysiology of necrotizing enterocolitis (NEC), including the role of platelet-activating factor (PAF).
  • To examine the current literature on the use of probiotics for NEC prevention in preterm infants.
  • To discuss concerns and considerations for the safe and optimal administration of probiotics.

Main Methods:

  • Literature review of research studies on NEC pathophysiology.
  • Review of studies investigating the role of platelet-activating factor (PAF) in NEC.
  • Systematic review of clinical trials and observational studies on probiotic use in preterm neonates.

Main Results:

  • Advances in neonatal medicine have improved survival rates for preterm infants.
  • Understanding of NEC pathophysiology has grown, highlighting the role of PAF.
  • Probiotics demonstrate potential as a preventative strategy for NEC, though optimal protocols are under investigation.

Conclusions:

  • NEC remains a critical challenge in neonatal intensive care.
  • Further research is needed to optimize probiotic administration for NEC prevention in preterm infants.
  • Ensuring the safe and effective use of probiotics is paramount for vulnerable neonates.